title: Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.
abstract: The determinants of a broad neutralizing antibody (NAb) response and its effect on human immunodeficiency virus type 1 (HIV-1) disease progression are not well defined, partly because most prior studies of a broad NAb response were cross-sectional. We examined correlates of NAb response breadth among 70 HIV-infected, antiretroviral-naïve Kenyan women from a longitudinal seroincident cohort. NAb response breadth was measured 5 years after infection against five subtype A viruses and one subtype B virus. Greater NAb response breadth was associated with a higher viral load set point and greater HIV-1 env diversity early in infection. However, greater NAb response breadth was not associated with a delayed time to a CD4(+) T-cell count of <200, antiretroviral therapy, or death. Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection.
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
authors.forename: Anne
authors.initials: A
authors.lastname: Piantadosi
authors.forename: Dana
authors.initials: D
authors.lastname: Panteleeff
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Blish
authors.forename: Jared M
authors.initials: JM
authors.lastname: Baeten
authors.forename: Walter
authors.initials: W
authors.lastname: Jaoko
authors.forename: R Scott
authors.initials: RS
authors.lastname: McClelland
authors.forename: Julie
authors.initials: J
authors.lastname: Overbaugh
mesh_terms: D044966:Anti-Retroviral Agents / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D015686:Gene Products, env / Q000235:genetics; D015683:Gene Products, gag / Q000235:genetics; D015658:HIV Infections / Q000175:diagnosis* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D020128:Inhibitory Concentration 50; D007630:Kenya; D009500:Neutralization Tests; D012367:RNA, Viral / Q000378:metabolism; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents; D015686:Gene Products, env; D015683:Gene Products, gag; D012367:RNA, Viral